Peptides and longevity: what the evidence actually supports

Why the excitement exists

Aging research has uncovered real mechanisms: cells lose the ability to repair DNA, mitochondria become less efficient, inflammation creeps upward and some signaling pathways shift. Several peptides interact with these processes in laboratory models, which makes them attractive candidates.

The trouble is the distance between a mechanism and an outcome. A compound that extends the life of worms or mice, or changes a marker in a cell culture, has not shown that it helps a 55-year-old live longer or better. That leap requires long, careful human studies, and for most longevity peptides they haven't been done.

What the research shows for common candidates

• Epitalon: a 2025 review in the International Journal of Molecular Sciences summarized decades of mostly cell and animal research, including telomerase effects in cultured cells. The authors stated that critical safety information is missing and called for toxicity, genotoxicity and cancer-risk studies before any approval.
• MOTS-c: a peptide encoded in mitochondrial DNA that improved glucose handling in mice. Human data are largely limited to measuring natural levels, not treatment trials.
• Growth hormone-releasing peptides such as sermorelin: they raise growth hormone and IGF-1, but higher growth signaling is not clearly a longevity strategy, and evidence for benefits in healthy middle-aged adults comes from small, short studies.
• NAD+ and its precursors: technically NAD+ is a coenzyme, not a peptide. A 2023 review in The Journals of Gerontology found oral NAD+ precursors safe and able to raise NAD+, but said clinical evidence that this improves physiological function is unclear.

Regulatory status matters here too

Epitalon and MOTS-c are not FDA-approved for any use. Both were previously listed by the FDA in its category of compounding substances with significant safety concerns; their nominations were withdrawn in April 2026. In July 2026, an FDA advisory committee voted to recommend each for the 503A bulks list for specific uses, against FDA staff advice. As of October 2026 the FDA had not completed rulemaking.

NAD is in the FDA's Category 1 for compounding, meaning it is under evaluation. None of these is an approved anti-aging treatment, and compounded versions are not FDA-approved.

Healthspan, not anti-aging

A more useful goal than "reversing aging" is healthspan: staying strong, mobile, mentally sharp and free of disability for as long as possible. That goal is measurable. You can track strength, walking speed, blood pressure, A1c, lipids, bone density and body composition.

Framing it this way also makes trade-offs clearer. A treatment with uncertain benefit and unknown long-term safety has to clear a high bar when the proven alternatives are free or inexpensive.

Red flags in longevity marketing

• Promises to reverse aging or add a specific number of years
• Heavy reliance on mouse, worm or cell studies presented as if they applied to people
• Personal transformation stories in place of trial data
• Claims that a product can substitute for sleep, exercise or medical care
• "Biological age" test results used to sell a product, without evidence the change matters for health

What still does most of the work

The CDC recommends at least 150 minutes of moderate aerobic activity and muscle-strengthening work on at least 2 days each week for adults. Adults also need 7 or more hours of sleep a night. Those habits affect heart disease, diabetes, cognition and muscle mass, which are the conditions that most shape how people age.

Add treatment of known risks, such as high blood pressure, high LDL cholesterol, prediabetes and untreated sleep apnea, and you have the core of a longevity plan with real evidence behind it.

Where peptides might fit

For some people, after the fundamentals are in place, a clinician may discuss an experimental option with clear expectations: it may do nothing, and long-term effects are unknown. HealifyMD clinicians frame any longevity peptide this way, start with biomarkers worth tracking and set a review point to decide whether to continue. Examples of listed prices: epithalon from $320/month, MOTS-c from $275/month and NAD+ injection from $199/month, confirmed at your eligibility review.